These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 19665589)

  • 41. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.
    Duncan JS; Litchfield DW
    Biochim Biophys Acta; 2008 Jan; 1784(1):33-47. PubMed ID: 17931986
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2.
    Spinello Z; Fregnani A; Quotti Tubi L; Trentin L; Piazza F; Manni S
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918307
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urolithin as a converging scaffold linking ellagic acid and coumarin analogues: design of potent protein kinase CK2 inhibitors.
    Cozza G; Gianoncelli A; Bonvini P; Zorzi E; Pasquale R; Rosolen A; Pinna LA; Meggio F; Zagotto G; Moro S
    ChemMedChem; 2011 Dec; 6(12):2273-86. PubMed ID: 21972104
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
    Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
    J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
    Quotti Tubi L; Canovas Nunes S; Brancalion A; Doriguzzi Breatta E; Manni S; Mandato E; Zaffino F; Macaccaro P; Carrino M; Gianesin K; Trentin L; Binotto G; Zambello R; Semenzato G; Gurrieri C; Piazza F
    Leukemia; 2017 Feb; 31(2):292-300. PubMed ID: 27479180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
    Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
    Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
    Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
    Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells.
    Ahmad KA; Harris NH; Johnson AD; Lindvall HC; Wang G; Ahmed K
    Mol Cancer Ther; 2007 Mar; 6(3):1006-12. PubMed ID: 17363494
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The selectivity of inhibitors of protein kinase CK2: an update.
    Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
    Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discrimination between the activity of protein kinase CK2 holoenzyme and its catalytic subunits.
    Salvi M; Sarno S; Marin O; Meggio F; Itarte E; Pinna LA
    FEBS Lett; 2006 Jul; 580(16):3948-52. PubMed ID: 16806200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of CK2 enhances UV-triggered apoptotic cell death in lung cancer cell lines.
    Zhao T; Jia H; Li L; Zhang G; Zhao M; Cheng Q; Zheng J; Li D
    Oncol Rep; 2013 Jul; 30(1):377-84. PubMed ID: 23595577
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chimeric peptides as modulators of CK2-dependent signaling: Mechanism of action and off-target effects.
    Zanin S; Sandre M; Cozza G; Ottaviani D; Marin O; Pinna LA; Ruzzene M
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1694-707. PubMed ID: 25936516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CK2 phosphorylation of C/EBPδ regulates its transcription factor activity.
    Schwind L; Zimmer AD; Götz C; Montenarh M
    Int J Biochem Cell Biol; 2015 Apr; 61():81-9. PubMed ID: 25680545
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
    Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
    Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.
    Trembley JH; Wang G; Unger G; Slaton J; Ahmed K
    Cell Mol Life Sci; 2009 Jun; 66(11-12):1858-67. PubMed ID: 19387548
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intracellular protein kinase CK2 inhibition by ferulic acid-based trimodal nanodevice.
    Zanin S; Molinari S; Cozza G; Magro M; Fedele G; Vianello F; Venerando A
    Int J Biol Macromol; 2020 Dec; 165(Pt A):701-712. PubMed ID: 33010276
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Protein kinase CK2 and human malignant tumors].
    Huang Y; Zhou S; Xue H; Zhao Z; Wang L
    Zhongguo Fei Ai Za Zhi; 2012 Jul; 15(7):439-45. PubMed ID: 22814265
    [No Abstract]   [Full Text] [Related]  

  • 58. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
    Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
    Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
    Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
    Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The dark side of protein kinase CK2 inhibition.
    Cozza G; Meggio F; Moro S
    Curr Med Chem; 2011; 18(19):2867-84. PubMed ID: 21651492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.